加载中
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
前收盘价
US$0.2456
−US$0.0304 · -11.01%
盘后
US$0.2509
+US$0.0053 · +2.16%
10月12日 19:53 ET
盘中时间采用ET。市场数据可能有所延迟。
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
日内区间
当前US$0.2456
52周区间
当前US$0.2456
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
60
合理估值
情绪
51
多空交织
风险
71
高风险
动量
21
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
日内区间
当前US$0.2456
52周区间
当前US$0.2456
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 409.4万 USD | 1418.1万 USD | 3304.6万 USD | 3475.4万 USD | 2572.8万 USD |
| 销售、一般及管理费用 | 1220.8万 USD | 1364.3万 USD | 1979万 USD | 1367.5万 USD | 1115.3万 USD |
| 营业费用 | 1280.3万 USD | −7298.5万 USD | 3.48亿 USD | 4842.9万 USD | 6584.7万 USD |
| 折旧和摊销 | 7.8万 USD | 9.7万 USD | 9.9万 USD | 6.8万 USD | 3000 USD |
| 营业利润 | −1280.3万 USD | 7298.5万 USD | −3.48亿 USD | −4842.9万 USD | −6584.7万 USD |
| 净利润 | −3922.2万 USD | 4200.5万 USD | −3.85亿 USD | −5255.6万 USD | −5563.7万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
评级样本有限，仅3项
报告持有此股票敞口的交易所交易基金。
State Street SPDR Portfolio Emerging Markets ETFSPEM
State Street SPDR S&P Emerging Markets Small Cap ETFEWX
Vanguard Extended Market ETFVXFAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
